Cureous Labs, a Bengaluru-based medtech startup, has raised ₹1.66 crore in a seed round backed by Inflection Point Ventures (IPV) and joined by Anthill Ventures.
The funds will be used to manufacture the first batch of Eturnal™, build inventory, expand the sales and business development team, launch the company’s first disinfection centre, and complete product safety testing and certifications.
The startup also plans to grow its B2B product portfolio in India.
Founded by Asish Mohandas in 2019, a Biodesign Fellow from AIIMS and IIT Delhi and the first National James Dyson Awardee for a medical device, Cureous Labs focuses on preventing pressure injuries and enhancing caregiver efficiency through affordable automation.
Its flagship device Eturnal™ is priced at one-fifth of international alternatives and is deployed across hospitals, rehabilitation centres, and home care setups.
Also Read | Refold AI Raises $6.5 Mn Seed Funding Led By Eniac Ventures & Tidal Ventures
The startup has recorded over 30,000 hours of use and 14,000 automated patient turns, and is running active B2B and B2C pilots across South India.
The global market for elderly and bedridden patient care is valued at $277 billion, with India’s total addressable market estimated at $8.34 billion.
